Hanmi Epe launch in Korea undercuts Mounjaro on starting price

The Hanmi Epe launch puts South Korea's first home-grown GLP-1 obesity medicine into doctors' hands from 29 October 2026, at a small group of medical institutions. Hanmi Pharmaceutical has set a supply price of 129,800 won for the first four weeks of efpeglenatide treatment, roughly half the four-week price of Eli Lilly's Mounjaro at its lowest dose, according to Korean press reports. Stock is limited at first, the company said, and the effect on a market run by two foreign brands will take time to judge.

Epe reaches Korean clinics after an October approval

Korea's Ministry of Food and Drug Safety approved Epe on 7 October, making it the first GLP-1 class obesity treatment developed in the country to win clearance, according to a JKN report. Hanmi began shipping the product on 22 October, and prescribing opened on 29 October at selected hospitals and clinics. In the broadcaster's translated report, a Hanmi official told SBS that "as the initial volume is not large, it will take some time until supply expands." The company did not name the first sites, the number of pens shipped or a date for wider supply. That gap matters for doctors and patients elsewhere in the country, who cannot yet plan around the drug. Neither report said where the medicine is made or how much Hanmi can produce each month.

As described in the reports, Epe is a prescription medicine for chronic weight management in adults with obesity who do not have diabetes, and in overweight adults with a body mass index of 27 kg/m² or higher who also have a weight-related illness. It is meant to be used together with a lower-calorie diet and more physical activity, not instead of them. The drug comes as an auto-injector used once a week under the skin. Doctors start patients on the lowest strength and raise it in steps toward a maintenance strength, so the dose has to be set and adjusted under medical care. The reports describe no approval outside Korea, so for now the Hanmi Epe launch is a purely domestic event.

Efpeglenatide results come from a Korean Phase 3 trial

The approval rests on a Korean Phase 3 trial in 448 adults with obesity or overweight who did not have diabetes, JKN reported. People who took efpeglenatide for 40 weeks lost 9.75% of their body weight on average, and Hanmi said some patients lost up to 30%. Participants were also asked to eat about 500 kilocalories less each day and to exercise for more than 150 minutes a week. The reports did not give the comparison group's result, the share of people who stopped treatment or a journal reference. Without those details, the drug's own effect beyond diet and exercise cannot be checked from what has been made public. The figure of up to 30% describes a few individuals, not a typical result.

People who took efpeglenatide for 40 weeks lost 9.75% of their body weight on average, and Hanmi said some patients lost up to 30%.

Both outlets said Epe's weight loss is known to be slightly lower than that of Mounjaro and Wegovy, although neither cited a direct comparison study. Hanmi is promoting the medicine as a "K-obesity drug", stressing that one Korean company handled every stage from finding the candidate to bringing it to market, and that its trial enrolled only Koreans. That message may help at home, but it also means the evidence comes from a single population. The approval names diarrhea, nausea, constipation, indigestion and skin reactions where the pen is used as the main side effects. JKN reported that the drug is ruled out for anyone who has had a rare thyroid cancer called medullary thyroid carcinoma, or the inherited condition known as MEN 2, and for people whose close relatives have had either one.

Starting price undercuts Mounjaro and Wegovy

Pricing for the Hanmi Epe launch rises as patients move up the strengths. The supply price is 129,800 won for weeks one to four, 228,800 won for weeks five to eight and 277,200 won for weeks nine to twelve. From week 13 it settles at 299,200 won for each four-week cycle. Both JKN and SBS said patients are likely to pay slightly more than these supply prices once the product reaches them. The five strengths carry supply prices between 24,200 won and 74,800 won each, figures SBS attributed to the pharmaceutical industry rather than to a published price list. Neither outlet mentioned insurance coverage, so the reports leave open how much of the cost falls on patients themselves.

The comparison the outlets drew is narrow. Mounjaro's four-week supply price at its lowest dose is about 270,000 won and Wegovy's is about 210,000 won, so Epe costs less in the opening month. At the maintenance stage, however, Epe's 299,200 won per cycle sits above both of those starting figures. The reports gave no rival prices at higher doses, so a like-for-like yearly cost cannot be built from them. Separately, the Korean regulator has just added new uses for Mounjaro to its label, so the incumbents are not standing still. What a patient pays over a year will depend on the strength reached, clinic fees and any pricing response from Lilly or Novo Nordisk.

Korea obesity drug market has two leaders

Until now the Korea obesity drug market for GLP-1 medicines has been effectively split between Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, which SBS said launched in August last year after Wegovy. The broadcaster put the annual size of the domestic GLP-1 obesity drug market at 2 trillion won and reported that Hanmi wants to turn the two-way contest into a three-way one. The Hanmi Epe launch is the first real test of whether a local maker can win share with a lower starting price and Korean trial data. Other Korean firms are also working on GLP-1 products, among them Daewon Pharmaceutical, which has reported early data on an oral semaglutide candidate that is not yet approved.

Market observers quoted by SBS said price competitiveness and proof of weight loss in everyday use will decide whether Epe succeeds. Hanmi said it plans to widen patient access and expand supply on the basis of quality control and what it called a reasonable pricing system, but it gave no volumes or dates. Several questions remain open. The first is how quickly stock reaches clinics beyond the initial group. The second is whether the full Phase 3 data appear in a peer-reviewed journal, which would let doctors judge the 9.75% figure against a comparison group. The third is whether Novo Nordisk or Lilly changes prices in Korea, and whether Hanmi seeks approval for Epe in other countries.

Conclusion

The Hanmi Epe launch gives Korean doctors a third GLP-1 option for weight management, with the cheapest reported starting month of the three brands and trial data drawn only from Korean adults. The trade-off, as both outlets reported, is weight loss that is known to be slightly lower than the market leaders, and a maintenance price above their reported starting prices. Limited early stock means most patients will wait. The next markers are supply volumes, full trial publication and any move by Novo Nordisk or Lilly. This report is for information only and is not medical advice.